

**PRECONFERENCE** Alzheimer's Imaging Consortium (AIC)

Saturday, July 27



**ORAL  
SESSION**

**2:20pm - 2:35pm (EST)**

**Genetic predisposition to AD and inflammation determine vulnerable brain regions to air pollution.**

PRESENTING AUTHOR

**Natàlia Vilor-Tejedor, PhD**

SESSION DETAILS

Scientific session: Neuroimaging correlates of risk and protective factors.

📍 Ballroom — Pennsylvania Convention Center.



**POSTERS**

**AIC-119**

**Genetic predisposition to clinical AD and AD pathology is differentially associated with baseline and 3-year period change for specific AD-related markers.**

PRESENTING AUTHOR

**Patricia Genius, MSc**

AREA

Biomarkers: Neuroimaging.

**AIC-309**

**Associations of 18F-RO-948 Tau PET with Fluid AD Biomarkers, Centiloid, and Cognition in the Early AD Continuum.**

PRESENTING AUTHOR

**Mahnaz Shekari, MSc**

AREA

Biomarkers: Neuroimaging.

**AIC-251**

**Neurobiological correlates of grey matter morphometry changes in preclinical Alzheimer's disease.**

PRESENTING AUTHOR

**Wiesje Pelkmans, PhD**

AREA

Biomarkers: Biomarkers (non-neuroimaging).

**AIC-196**

**Aberrant resting-state functional connectivity of the default-mode network relates to cognitive decline in the earliest Alzheimer's continuum.**

PRESENTING AUTHOR

**Michalis Kassinopoulos, PhD**

AREA

Biomarkers: Neuroimaging.

**AIC-197**

**Cognitive reserve is associated with the recruitment of compensatory brain networks in individuals at risk for Alzheimer's disease.**

PRESENTING AUTHOR

**Michalis Kassinopoulos, PhD**

AREA

Biomarkers: Neuroimaging.

**AAIC**

Sunday, July 28 (1/2)



**POSTERS**

**Sunday-21**

**Genetic proxies for predicting plasma protein levels reveal TIMP2 role in human cognitive performance.**

PRESENTING AUTHOR

**Federica Anastasi, PhD**

AREA

Genetics: Basic Science and Pathogenesis.

**Sunday-358**

**Longer leukocyte telomere length is associated with lower markers of early Alzheimer's disease pathology, astrocytic reactivity, and synaptic dysfunction.**

PRESENTING AUTHOR

**Blanca Rodríguez-Fernández, MSc**

AREA

Biomarkers: Biomarkers (non-neuroimaging).

**Sunday-276**

**Synaptic dysfunction mediates the association between the CSF t-tau and PACC change among cognitively unimpaired multiparous women.**

PRESENTING AUTHOR

**Anna Brugulat-Serrat, PhD**

AREA

Biomarkers: Biomarkers (non-neuroimaging).

**Sunday-451**

**Aberrant resting-state functional connectivity of the default-mode network relates to cognitive decline in the earliest Alzheimer's continuum.**

PRESENTING AUTHOR

**Michalis Kassinopoulos, PhD**

AREA

Biomarkers: Neuroimaging.

**Sunday-452**

**Cognitive reserve is associated with the recruitment of compensatory brain networks in individuals at risk for Alzheimer's disease.**

PRESENTING AUTHOR

**Michalis Kassinopoulos, PhD**

AREA

Biomarkers: Neuroimaging.

**Sunday-534**

**The relationship between dyadic perspective in subjective reports and objective cognitive decline in preclinical Alzheimer's.**

PRESENTING AUTHOR

**David López-Martos, MSc**

AREA

Clinical Manifestations: Neuropsychiatry and Behavioral Neurology.

AAIC

Sunday, July 28 (2/2)



**LIGHTNING  
PRESENTATION  
ROUND**

8:00am - 8:04am (EST)

**Performance of plasma  
NTK biomarkers to detect  
amyloid-β pathology in  
cognitively unimpaired  
individuals at risk  
of Alzheimer's disease.**

PRESENTING AUTHOR

**Armand González Escalante, MSc**

SESSION DETAILS

Biomarkers LPR: Fluid biomarker session.

📍 118ABC — Pennsylvania Convention Center.



**FEATURED  
RESEARCH  
SESSION**

2:50pm - 3:00pm (EST)

**Sensitive methods to define  
subtle memory decline  
capture intra-individual  
hippocampal atrophy and  
increased cortical volumes  
in preclinical Alzheimer's.**

PRESENTING AUTHOR

**David López-Martos, MSc**

SESSION DETAILS

Technological advances in neuropsychology to enhance detection, relationship with biomarkers and responsiveness.

📍 120ABC — Pennsylvania Convention Center.



**AAIC**

Monday, July 29



**POSTERS**

**Monday-256**

**Plasma biomarkers combinations for prescreening rapid amyloid accumulation in cognitively unimpaired individuals at-risk of Alzheimer's disease.**

PRESENTING AUTHOR

**José Contador, MD, PhD**

AREA

Biomarkers: Biomarkers (non-neuroimaging).

**Monday-236**

**Plasma biomarkers discrimination accuracy of biologically defined Alzheimer's disease in a memory clinic setting.**

PRESENTING AUTHOR

**Federica Anastasi, PhD**

AREA

Biomarkers: Biomarkers (non-neuroimaging).

**Monday-245**

**Assessing the impact of fasting condition and storage time on plasma amyloid-β 42 and 40, pTau181, Nf-L and GFAP measurements.**

PRESENTING AUTHOR

**Helena Blasco-Forniés, MSc**

AREA

Biomarkers: Biomarkers (non-neuroimaging).

**Monday-166**

**Unravelling neurodegenerative effects of SARS-CoV-2 infection in Alzheimer's disease- brain organoids.**

PRESENTING AUTHOR

**Laura Garcia Gonzalez, PhD**

AREA

Basic Science and Pathogenesis: Molecular and Cell Biology.



**FEATURED RESEARCH SESSION**

**9:36am - 9:48am (EST)**

**Plasma Biomarkers for Accelerated Cognitive Decline: A Tool for Targeted Clinical Trial Recruitment.**

PRESENTING AUTHOR

**Marc Suarez-Calvet, MD, PhD**

SESSION DETAILS

Development of Blood-based Biomarkers for Assessment of Alzheimer's Disease.

📍 118ABC — Pennsylvania Convention Center.

**AAIC**

Tuesday, July 30



**POSTERS**

**Tuesday- 486**

**Genetic predisposition to AD and inflammation determine vulnerable brain regions to air pollution.**

PRESENTING AUTHOR

**Natàlia Vilor-Tejedor, PhD**

AREA

Biomarkers: Neuroimaging.

**Tuesday-393**

**Genetic predisposition to clinical AD and AD pathology is differentially associated with baseline and 3-year period change for specific AD-related markers.**

PRESENTING AUTHOR

**Patricia Genius, MSc**

AREA

Biomarkers: Neuroimaging.

**Tuesday-468**

**Associations of 18F-RO-948 Tau PET with Fluid AD Biomarkers, Centiloid, and Cognition in the Early AD Continuum.**

PRESENTING AUTHOR

**Mahnaz Shekari, MSc**

AREA

Biomarkers: Neuroimaging.

**Tuesday-770**

**Early amyloid accumulation and APOE-ε4 are associated with reduced non-rapid eye movement slow-wave activity in cognitively unimpaired adults.**

PRESENTING AUTHOR

**Núria Tort-Colet, PhD**

AREA

Public Health: Prevention (nonpharmacological).

**Tuesday-266**

**APOE-ε4 carriership modifies the association of CCL11 and sVCAM1 plasma protein levels with cognitive performance in individuals at risk of Alzheimer's disease.**

PRESENTING AUTHOR

**Luis Felipe Hernández-Villamizar, MSc**

AREA

Biomarkers: Biomarkers (non-neuroimaging).

**Tuesday-409**

**Unmasking early cerebral blood flow alterations with time-encoded ASL in Alzheimer's continuum.**

PRESENTING AUTHOR

**Michalis Kassinopoulos, PhD**

AREA

Biomarkers: Neuroimaging.

**AAIC**

Wednesday, July 31



**FEATURED  
RESEARCH  
SESSION**

**2:00pm - 2:10pm (EST)**

**Psychological effects  
of personalized dementia risk  
disclosure: The Barcelonaβeta  
Dementia Prevention Research  
Clinic study.**

PRESENTING AUTHOR

**Marc Suarez-Calvet, MD, PhD**

SESSION DETAILS

From prioritization to care provision: Current  
directions in disease-modifying treatments.

**Nutter Theater**  
— Pennsylvania Convention Center.

**2:30pm - 2:40 pm (EST)**

**Neurobiological correlates  
of grey matter morphometry  
changes in preclinical Alzheimer's  
disease.**

PRESENTING AUTHOR

**Wiesje Pelkmans, PhD**

SESSION DETAILS

Mapping neurobiological progression through  
imaging subtypes.

**115 ABC**  
— Pennsylvania Convention Center.